Posted by Michael Wonder on 24 Apr 2019
AbbVie expands immunology portfolio in the U.S. with FDA approval of Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis
23 April 2019 - AbbVie today announced that the U.S. FDA approved Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
In clinical trials, Skyrizi produced high rates of durable skin clearance – most people (82 and 81%) treated with Skyrizi achieved 90% skin clearance (PASI 90) at one year, with the majority (56 and 60%) achieving complete skin clearance (PASI 100).
